Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.

Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, Annunziata M, Stagno F, Tiribelli M, Binotto G, Bonifacio M, Fava C, Iurlo A, Bucelli C, Mansueto G, Gozzini A, Falzetti F, Montefusco E, Crisà E, Gugliotta G, Russo S, Cedrone M, RussoRossi A, Pregno P, Isidori A, Mauro E, Atelda R, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Galimberti S, Orlandi E, Calistri E, Bocchia M, Cavazzini F, Rege Cambrin G, Orofino N, Luciano L, Sgherza N, Rosti G, Latagliata R, Capodanno I.

Ann Hematol. 2019 Aug 7. doi: 10.1007/s00277-019-03767-y. [Epub ahead of print]

PMID:
31392461
2.

Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.

Dragani M, Rege-Cambrin G, Ferrero D, Abruzzese E, Pregno P, Elena C, Cedrone M, Santoro M, Andreani G, Saglio G, Fava C.

Leuk Lymphoma. 2019 Jun 4:1-3. doi: 10.1080/10428194.2019.1622103. [Epub ahead of print] No abstract available.

PMID:
31161827
3.

Chronic Myeloid Leukemia Patient's Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial.

Borghi L, Galimberti S, Baratè C, Bonifacio M, Capochiani E, Cuneo A, Falzetti F, Iurlo A, Lunghi F, Minotto C, Orlandi EM, Rege-Cambrin G, Sica S, Supekar S, Haenig J, Vegni E.

Front Psychol. 2019 Feb 20;10:329. doi: 10.3389/fpsyg.2019.00329. eCollection 2019.

4.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

5.

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.

Iurlo A, Galimberti S, Abruzzese E, Annunziata M, Bonifacio M, Latagliata R, Pregno P, Ferrero D, Sorà F, Orlandi EM, Fava C, Cattaneo D, Bucelli C, Binotto G, Pungolino E, Tiribelli M, Gozzini A, Gugliotta G, Castagnetti F, Stagno F, Rege-Cambrin G, Martino B, Luciano L, Breccia M, Sica S, Bocchia M, Pane F, Saglio G, Rosti G, Specchia G, Cortelezzi A, Baccarani M.

Ann Hematol. 2018 Jan;97(1):95-100. doi: 10.1007/s00277-017-3144-1. Epub 2017 Oct 2.

PMID:
28971265
6.

CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.

Dogliotti I, Fava C, Serra A, Gottardi E, Daraio F, Carnuccio F, Giugliano E, Bocchia M, Saglio G, Rege-Cambrin G.

Stem Cell Investig. 2017 Jun 23;4:57. doi: 10.21037/sci.2017.06.02. eCollection 2017.

7.

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.

Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A.

Oncotarget. 2016 Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657.

8.

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.

Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S96-S100. doi: 10.1016/j.clml.2016.03.008. Epub 2016 Apr 1. Review.

PMID:
27131622
9.

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Gozzini A, Usala E, Carella AM, Rege-Cambrin G, Martino B, Abruzzese E, Albano F, Stagno F, Luciano L, D'Adda M, Bocchia M, Cavazzini F, Tiribelli M, Lunghi M, Pia Falcone A, Musolino C, Levato L, Venturi C, Soverini S, Cavo M, Alimena G, Pane F, Martinelli G, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Am J Hematol. 2016 Jun;91(6):617-22. doi: 10.1002/ajh.24362. Epub 2016 Apr 24.

10.

Dasatinib first-line: Multicentric Italian experience outside clinical trials.

Breccia M, Stagno F, Luciano L, Abruzzese E, Annunziata M, D'Adda M, Maggi A, Sgherza N, Russo-Rossi A, Pregno P, Castagnetti F, Iurlo A, Latagliata R, Cedrone M, Di Renzo N, Sorà F, Rege-Cambrin G, La Nasa G, Scortechini AR, Greco G, Franceschini L, Sica S, Bocchia M, Crugnola M, Orlandi E, Guarini A, Specchia G, Rosti G, Saglio G, Alimena G.

Leuk Res. 2016 Jan;40:24-9. doi: 10.1016/j.leukres.2015.11.008. Epub 2015 Nov 17.

PMID:
26643920
11.

Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH.

Rosso V, Bracco E, Pedrola R, Carturan S, Signorino E, Petiti J, Calabrese C, Nicoli P, De Gobbi M, Gaidano V, Gallo D, Ulisciani S, Fava C, Rege-Cambrin G, Frassoni F, Saglio G, Cilloni D.

Biomark Res. 2015 Jul 3;3:15. doi: 10.1186/s40364-015-0039-y. eCollection 2015.

12.

Update on emerging treatments for chronic myeloid leukemia.

Fava C, Morotti A, Dogliotti I, Saglio G, Rege-Cambrin G.

Expert Opin Emerg Drugs. 2015 Jun;20(2):183-96. doi: 10.1517/14728214.2015.1031217. Epub 2015 Mar 31. Review.

PMID:
25826695
13.

The choice of first-line chronic myelogenous leukemia treatment.

Fava C, Rege-Cambrin G, Saglio G.

Ann Hematol. 2015 Apr;94 Suppl 2:S123-31. doi: 10.1007/s00277-015-2321-3. Epub 2015 Mar 27. Review.

14.

Morgana acts as an oncosuppressor in chronic myeloid leukemia.

Di Savino A, Panuzzo C, Rocca S, Familiari U, Piazza R, Crivellaro S, Carrà G, Ferretti R, Fusella F, Giugliano E, Camporeale A, Franco I, Miniscalco B, Cutrin JC, Turco E, Silengo L, Hirsch E, Rege-Cambrin G, Gambacorti-Passerini C, Pandolfi PP, Papotti M, Saglio G, Tarone G, Morotti A, Brancaccio M.

Blood. 2015 Apr 2;125(14):2245-53. doi: 10.1182/blood-2014-05-575001. Epub 2015 Feb 12.

15.

Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome.

Cardinale L, Asteggiano F, Moretti F, Torre F, Ulisciani S, Fava C, Rege-Cambrin G.

World J Radiol. 2014 Aug 28;6(8):583-8. doi: 10.4329/wjr.v6.i8.583. Review.

16.

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

Breccia M, Alimena G, Baccarani M, Bocchia M, Di Raimondo F, Gambacorti-Passerini C, Gozzini A, Morra E, Pane F, Pregno P, Rege-Cambrin G, Rosti G, Specchia G, Vigneri P, Saglio G.

Crit Rev Oncol Hematol. 2014 Jun;90(3):181-9. doi: 10.1016/j.critrevonc.2013.12.010. Epub 2013 Dec 17.

PMID:
24405858
17.

Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.

Fava C, Rege-Cambrin G, Busca A, Gottardi E, Daraio F, Saglio G.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S272-5. doi: 10.1016/j.clml.2013.05.017. No abstract available.

PMID:
24290212
18.

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.

Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G.

Drugs Aging. 2013 Aug;30(8):629-37. doi: 10.1007/s40266-013-0088-6.

PMID:
23681399
19.

Chronic myeloid leukemia: state of the art in 2012.

Fava C, Rege-Cambrin G, Saglio G.

Curr Oncol Rep. 2012 Oct;14(5):379-86. doi: 10.1007/s11912-012-0253-9. Review.

PMID:
22821153
20.

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, Specchia G, Zanatta L, Rege-Cambrin G, Mancini M, Abruzzese E, Zaccaria A, Grimoldi MG, Gozzetti A, Ameli G, Capucci MA, Palka G, Bernasconi P, Palandri F, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M, Testoni N; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML.

Blood. 2012 Jul 26;120(4):761-7. Epub 2012 Jun 12. Erratum in: Blood. 2013 Jun 27;121(26):5259. Cambrin, Rege [corrected to Rege-Cambrin, Giovanna].

21.

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.

Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Müller MC, Hochhaus A, Chuah C, Dufva IH, Rege-Cambrin G, Saglio G, Michallet M, Labussière H, Morisset S, Hayette S, Etienne G, Olavarria E, Zhou W, Peter S, Apperley JF, Cortes J.

Blood. 2011 Nov 17;118(20):5697-700. doi: 10.1182/blood-2011-07-367326. Epub 2011 Sep 16.

22.

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.

Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, Fava C, Cavazzini F, Annunziata M, Russo Rossi A, Pregno P, Abruzzese E, Vigneri P, Rege-Cambrin G, Sica S, Pane F, Santini V, Specchia G, Rosti G, Alimena G.

Haematologica. 2011 Oct;96(10):1457-61. doi: 10.3324/haematol.2011.041251. Epub 2011 Jun 17.

23.

Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution.

Falchi L, Rege-Cambrin G, Fava C, Donti E, Luzi D, Giugliano E, Gubbiotti M, Schippa M, Liberati AM.

Cancer Genet Cytogenet. 2010 Jun;199(2):139-42. doi: 10.1016/j.cancergencyto.2010.02.008.

PMID:
20471518
24.

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.

Palandri F, Castagnetti F, Iacobucci I, Martinelli G, Amabile M, Gugliotta G, Poerio A, Testoni N, Breccia M, Bocchia M, Crugnola M, Rege-Cambrin G, Martino B, Pierri I, Radaelli F, Specchia G, Pane F, Saglio G, Rosti G, Baccarani M.

Haematologica. 2010 Aug;95(8):1415-9. doi: 10.3324/haematol.2009.021246. Epub 2010 Mar 19.

25.

Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological study.

Matteucci C, Barba G, Varasano E, Vitale A, Mancini M, Testoni N, Cuneo A, Rege-Cambrin G, Elia L, La Starza R, Pierini V, Brandimarte L, Vignetti M, Foà R, Mecucci C; GIMEMA Acute Leukaemia Working Party, Italy.

Br J Haematol. 2010 Apr;149(1):70-8. doi: 10.1111/j.1365-2141.2009.08056.x. Epub 2010 Jan 11.

PMID:
20067559
26.

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.

Testoni N, Marzocchi G, Luatti S, Amabile M, Baldazzi C, Stacchini M, Nanni M, Rege-Cambrin G, Giugliano E, Giussani U, Abruzzese E, Kerim S, Grimoldi MG, Gozzetti A, Crescenzi B, Carcassi C, Bernasconi P, Cuneo A, Albano F, Fugazza G, Zaccaria A, Martinelli G, Pane F, Rosti G, Baccarani M.

Blood. 2009 Dec 3;114(24):4939-43. doi: 10.1182/blood-2009-07-229864. Epub 2009 Oct 1.

27.

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, Testoni N, Rege-Cambrin G, Santucci A, Vignetti M, Fazi P, Martelli MP, Haferlach T, Falini B.

Blood. 2009 Oct 1;114(14):3024-32. doi: 10.1182/blood-2009-01-197871. Epub 2009 May 8.

28.

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.

Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth-Hansen H, Kairisto V, Levato L, Martinelli G, Nagler A, Lanng Nielsen J, Ozbek U, Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O, Saglio G, Simonsson B.

Blood. 2009 May 7;113(19):4497-504. doi: 10.1182/blood-2008-12-191254. Epub 2009 Mar 4.

29.

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.

Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party.

Blood. 2009 Apr 9;113(15):3428-34. doi: 10.1182/blood-2007-08-103499. Epub 2009 Feb 11.

30.

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.

Palandri F, Iacobucci I, Soverini S, Castagnetti F, Poerio A, Testoni N, Alimena G, Breccia M, Rege-Cambrin G, Tiribelli M, Varaldo R, Abruzzese E, Martino B, Luciano L, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G.

Clin Cancer Res. 2009 Feb 1;15(3):1059-63. doi: 10.1158/1078-0432.CCR-08-1195.

31.

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.

Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S, Rege-Cambrin G, Stagno F, Specchia G, Martino B, Levato L, Merante S, Liberati AM, Pane F, Saglio G, Alberti D, Martinelli G, Baccarani M, Rosti G.

Haematologica. 2009 Feb;94(2):205-12. doi: 10.3324/haematol.13529. Epub 2009 Jan 14.

32.

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.

Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Haematologica. 2008 Dec;93(12):1792-6. doi: 10.3324/haematol.13068. Epub 2008 Oct 6.

33.

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brümmendorf TH, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM, Talpaz M.

Leukemia. 2008 Dec;22(12):2176-83. doi: 10.1038/leu.2008.221. Epub 2008 Aug 28.

PMID:
18754032
34.

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

Saglio G, Ulisciani S, Bosa M, Cilloni D, Rege-Cambrin G.

Leuk Lymphoma. 2008 Apr;49(4):625-8. doi: 10.1080/10428190801896210. Review.

PMID:
18398722
35.

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.

Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML.

Haematologica. 2008 May;93(5):770-4. doi: 10.3324/haematol.12265. Epub 2008 Mar 26.

36.

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.

Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, Gollerkeri A, Coutre S.

Blood. 2007 Oct 1;110(7):2309-15. Epub 2007 May 11.

37.

Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party.

Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, Poerio A, Soverini S, Palandri F, Rege Cambrin G, Iuliano F, Alimena G, Latagliata R, Testoni N, Pane F, Saglio G, Baccarani M, Martinelli G.

Haematologica. 2007 Jan;92(1):101-5.

38.

Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.

Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Foà R, Baccarani M, Mandelli F.

Blood. 2007 May 1;109(9):3676-8. Epub 2007 Jan 9.

39.

NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line.

Morotti A, Cilloni D, Pautasso M, Messa F, Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza A, Taulli R, Bracco E, Rege-Cambrin G, Gottardi E, Saglio G.

Am J Hematol. 2006 Dec;81(12):938-45.

40.

Corticosteroids can reverse severe imatinib-induced hepatotoxicity.

Ferrero D, Pogliani EM, Rege-Cambrin G, Fava C, Mattioli G, Dellacasa C, Campa E, Perfetti P, Fumagalli M, Boccadoro M.

Haematologica. 2006 Jun;91(6 Suppl):ECR27.

41.

Trisomy 11 in myeloid malignancies is associated with internal tandem duplication of both MLL and FLT3 genes.

Rege-Cambrin G, Giugliano E, Michaux L, Stul M, Scaravaglio P, Serra A, Saglio G, Hagemeijer A.

Haematologica. 2005 Feb;90(2):262-4.

42.

Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia.

Saglio G, Morotti A, Mattioli G, Messa E, Giugliano E, Volpe G, Rege-Cambrin G, Cilloni D.

Ann N Y Acad Sci. 2004 Dec;1028:423-31. Review.

PMID:
15650267
43.

Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.

Cilloni D, Messa F, Gottardi E, Fava M, Arruga F, Defilippi I, Carturan S, Messa E, Morotti A, Giugliano E, Rege-Cambrin G, Alberti D, Baccarani M, Saglio G.

Cancer. 2004 Sep 1;101(5):979-88.

44.

Epcr 23 bp insertion in a patient with severe progressive arterial disease: a dominant loss of function mutant in conditions of increased APC request?

Zecchina G, Bosio S, Brusa E, Rege-Cambrin G, Camaschella C.

Br J Haematol. 2002 Dec;119(3):881-2. No abstract available.

PMID:
12437679
45.

Two new translocations involving the 11q23 region map outside the MLL locus in myeloid leukemias.

Giugliano E, Rege-Cambrin G, Scaravaglio P, Wlodarska I, Emanuel B, Stul M, Serra A, Tonso A, Pini M, Saglio G, Hagemeijer A.

Haematologica. 2002 Oct;87(10):1014-20.

46.

Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients.

Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, Rege-Cambrin G, Guerrasio A, Divona M, Lo Coco F, Saglio G.

Leukemia. 2002 Oct;16(10):2115-21.

47.

Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia.

Mancini M, Vegna ML, Castoldi GL, Mecucci C, Spirito F, Elia L, Tafuri A, Annino L, Pane F, Rege-Cambrin G, Gottardi M, Leoni P, Gallo E, Camera A, Luciano L, Specchia G, Torelli G, Sborgia M, Gabbas A, Tedeschi A, Della Starza I, Cascavilla N, Di Raimondo F, Mandelli F, Foà R.

Leukemia. 2002 Oct;16(10):2055-61.

48.

Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype.

Cuneo A, Bigoni R, Cavazzini F, Bardi A, Roberti MG, Agostini P, Tammiso E, Ciccone N, Mancini M, Nanni M, De Cuia R, Divona M, La Starza R, Crescenzi B, Testoni N, Rege Cambrin G, Mecucci C, Lo Coco F, Saglio G, Castoldi G.

Leukemia. 2002 Sep;16(9):1745-51.

49.

A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation.

Saglio G, Storlazzi CT, Giugliano E, Surace C, Anelli L, Rege-Cambrin G, Zagaria A, Jimenez Velasco A, Heiniger A, Scaravaglio P, Torres Gomez A, Roman Gomez J, Archidiacono N, Banfi S, Rocchi M.

Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9882-7. Epub 2002 Jul 11.

50.

From genes to therapy: the case of Philadelphia chromosome-positive leukemias.

Cilloni D, Guerrasio A, Giugliano E, Scaravaglio P, Volpe G, Rege-Cambrin G, Saglio G.

Ann N Y Acad Sci. 2002 Jun;963:306-12.

PMID:
12095956

Supplemental Content

Loading ...
Support Center